The PI3K Pathway As Drug Target in Human Cancer

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2010 Jan 21

PMID 20085938

Citations 560

Authors

Kevin D Courtney

Ryan B Corcoran

Jeffrey A Engelman

Affiliations

Soon will be listed here.

Abstract

The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth, survival, motility, and metabolism. This pathway is activated by several different mechanisms in cancers, including somatic mutation and amplification of genes encoding key components. In addition, PI3K signaling may serve integral functions for noncancerous cells in the tumor microenvironment. Consequently, therapeutics targeting the PI3K pathway are being developed at a rapid pace, and preclinical and early clinical studies are beginning to suggest specific strategies to effectively use them. However, the central role of PI3K signaling in a large array of diverse biologic processes raises concerns about its use in therapeutics and increases the need to develop sophisticated strategies for its use. In this review, we will discuss how PI3K signaling affects the growth and survival of tumor cells. From this vantage, we will consider how inhibitors of the PI3K signaling cascade, either alone or in combination with other therapeutics, can most effectively be used for the treatment of cancer.

Citing Articles

Metformin and glioma: Targeting metabolic dysregulation for enhanced therapeutic outcomes.

Basheer H, Salman N, Abdullah R, Elsalem L, Afarinkia K Transl Oncol. 2025; 53:102323.

PMID: 39970627 PMC: 11876755. DOI: 10.1016/j.tranon.2025.102323.

Comprehensive pan-cancer analysis of HSPG2 as a marker for prognosis.

Chen F, Gu X, Qiang G BMC Med Genomics. 2025; 18(1):33.

PMID: 39956899 PMC: 11831783. DOI: 10.1186/s12920-025-02103-w.

Mechanistic Approach into 1,2,3-triazoles-based IIIM(S)-RS98 Mediated Apoptosis in Lung Cancer Cells.

Dolkar R, Paudwal G, Singh D, Behera C, Malik S, Ali S AAPS J. 2025; 27(1):35.

PMID: 39900819 DOI: 10.1208/s12248-025-01018-9.

Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics.

Das S, Samaddar S Cancers (Basel). 2025; 17(2).

PMID: 39858036 PMC: 11764476. DOI: 10.3390/cancers17020255.

PI3K/AKT/mTOR Targeting in Colorectal Cancer Radiotherapy: A Systematic Review.

Mousavikia S, Darvish L, Firouzjaei A, Toossi M, Azimian H J Gastrointest Cancer. 2025; 56(1):52.

PMID: 39849185 DOI: 10.1007/s12029-024-01160-1.

References

Pacold M, Suire S, Perisic O, Davis C, WALKER E, Hawkins P . Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell. 2001; 103(6):931-43. DOI: 10.1016/s0092-8674(00)00196-3. View

Crowder R, Phommaly C, Tao Y, Hoog J, Luo J, Perou C . PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 2009; 69(9):3955-62. PMC: 2811393. DOI: 10.1158/0008-5472.CAN-08-4450. View

Engelman J, Mukohara T, Zejnullahu K, Lifshits E, Borras A, Gale C . Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006; 116(10):2695-706. PMC: 1570180. DOI: 10.1172/JCI28656. View

Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J . Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005; 65(11):4562-7. DOI: 10.1158/0008-5472.CAN-04-4114. View

Shalev N, Wong M, Mills G, Yount G, Stokoe D . Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol. 1998; 8(21):1195-8. DOI: 10.1016/s0960-9822(07)00493-9. View

Majumder P, Sellers W . Akt-regulated pathways in prostate cancer. Oncogene. 2005; 24(50):7465-74. DOI: 10.1038/sj.onc.1209096. View

Bellacosa A, De Feo D, Godwin A, BELL D, Cheng J, Altomare D . Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995; 64(4):280-5. DOI: 10.1002/ijc.2910640412. View

Shayesteh L, Lu Y, Kuo W, Baldocchi R, Godfrey T, Collins C . PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999; 21(1):99-102. DOI: 10.1038/5042. View

Meric-Bernstam F, Gonzalez-Angulo A . Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27(13):2278-87. PMC: 2738634. DOI: 10.1200/JCO.2008.20.0766. View

10.

Cheng J, Godwin A, Bellacosa A, Taguchi T, Franke T, Hamilton T . AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A. 1992; 89(19):9267-71. PMC: 50107. DOI: 10.1073/pnas.89.19.9267. View

11.

Taniguchi C, Tran T, Kondo T, Luo J, Ueki K, Cantley L . Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci U S A. 2006; 103(32):12093-7. PMC: 1524929. DOI: 10.1073/pnas.0604628103. View

12.

Kaplan D, Whitman M, Schaffhausen B, Pallas D, White M, Cantley L . Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell. 1987; 50(7):1021-9. DOI: 10.1016/0092-8674(87)90168-1. View

13.

Samuels Y, Velculescu V . Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004; 3(10):1221-4. DOI: 10.4161/cc.3.10.1164. View

14.

Stommel J, Kimmelman A, Ying H, Nabioullin R, Ponugoti A, Wiedemeyer R . Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007; 318(5848):287-90. DOI: 10.1126/science.1142946. View

15.

Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y . The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer. 2009; 101(1):145-8. PMC: 2713716. DOI: 10.1038/sj.bjc.6605109. View

16.

Hresko R, Mueckler M . mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005; 280(49):40406-16. DOI: 10.1074/jbc.M508361200. View

17.

Shaw R, Cantley L . Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441(7092):424-30. DOI: 10.1038/nature04869. View

18.

Vasudevan K, Barbie D, Davies M, Rabinovsky R, McNear C, Kim J . AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009; 16(1):21-32. PMC: 2752826. DOI: 10.1016/j.ccr.2009.04.012. View

19.

Kang S, Denley A, Vanhaesebroeck B, Vogt P . Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2006; 103(5):1289-94. PMC: 1360601. DOI: 10.1073/pnas.0510772103. View

20.

Cho H, Mu J, Kim J, Thorvaldsen J, Chu Q, Crenshaw 3rd E . Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001; 292(5522):1728-31. DOI: 10.1126/science.292.5522.1728. View